Focus on aripiprazole: A review of its use in child and adolescent psychiatry

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 18, Issue 3, 2009, Pages 250-260

  Greenaway, Masa'il ^a,b   Elbe, Dean ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DANTROLENE; LORAZEPAM; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; ZIPRASIDONE;

ABDOMINAL PAIN; AGGRESSION; AKATHISIA; ANXIETY DISORDER; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT; BULIMIA; CATATONIA; CHILD PSYCHIATRY; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONDUCT DISORDER; CONFUSION; CONSTIPATION; COUGHING; CREATINE KINASE BLOOD LEVEL; DELUSIONAL DISORDER; DEVELOPMENTAL DISORDER; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUENCY DISORDER; FOOD; FOOD DRUG INTERACTION; GILLES DE LA TOURETTE SYNDROME; GLUCOSE METABOLISM; HEADACHE; HEMIPLEGIA; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERSOMNIA; HYPONATREMIA; IRRITABILITY; KETONURIA; LETHARGY; LEUKOCYTE; LIBIDO DISORDER; LIPID METABOLISM; LISTLESSNESS; MANIC PSYCHOSIS; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA AND VOMITING; NECK PAIN; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; OCULOGYRIC CRISIS; OROFACIAL DYSKINESIA; PERSONALITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PHARYNGITIS; POLYDIPSIA; POLYURIA; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; RHINITIS; RIGIDITY; SALIVATION DISORDER; SCHIZOPHRENIA; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; SPEECH DISORDER; STOMACH PAIN; SUICIDAL IDEATION; SWEATING; THORAX PAIN; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; TORTICOLLIS; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

EID: 70349173443     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Bachmann, C. J., Rieger-Gies, A., Heinzel-Gutenbrunner, M., Hiemke, C., Remschmidt, H., & Theisen, F. M. (2008). Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Therapeutic Drug Monitoring, 30(4), 462-6.
2. Bachmann, C. J., Nicksch, B., de Lange, D., Theisen, F. M., & Remschmidt, H. (2007). Repeated creatine kinase elevation under treatment with quetiapine, clozapine, and aripiprazole in an adolescent. Journal of Clinical Psychopharmacology, 27(6), 710-711.
3. Barrett, E., Blonde, L., Clement, S., Davis, J., Devlin, J., Kane, J. et al. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596-601.
4. Barzman, D. H., DelBello, M. P., Kowatch, R. A., Gernert, B., Fleck, D. E., Pathak, S., et al. (2004). The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 14(4), 593-600.
5. Bastiaens, L. (2009). A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. Community Mental Health Journal, 45(1), 73-77.
6. Biederman, J., Mick, E., Spencer, T., Doyle, R., Joshi, G., Hammerness, P. et al. (2007). An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectrum, 12(9), 683-689.
7. Bristol Myers Squibb Canada (2009). Abilify® Product Monograph. Montreal, QC: Bristol Myers Squibb Canada.
8. Budman, C., Coffey, B. J., Shechter, R., Schrock, M., Wieland, N., Spirgel, A. et al. (2008). Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child and Adolescent Psychopharmacology, 18(5), 509-515.
9. Centre for Evidence Based Medicine (2009). Levels of evidence. Retrieved July 7, 2009, from http://www.cebm.net/index.aspx?o=1025.
10. Corey-Lisle, P., Guo, Z., Manos, G., Carson, W. H., McQuade, R. D., Pikalov A. et al. (2009). Effect of Aripiprazole on Quality of Life and Caregiver Strain in the Treatment of Irritability Associated with Autistic Disorder (CN138-178/179). Poster presented at the 162nd Annual Meeting of the American Psychiatric Association, San Francisco, CA.
11. Curtis, A. R., & Richards, R. W. (2007). The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine. Annals of Clinical Psychiatry, 19(3), 199-200.
12. Davies, L., Stern, J. S., Agrawal, N., & Robertson, M. M. (2006). A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Human Psychopharmacology, 21(7), 447-53.
13. Dhamija, R., & Verma, R. (2008). Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. Diabetes Care, 31(6), e50.
14. Duane, D. D. (2006). Aripiprazole in childhood and adolescence for Tourette syndrome. Journal of Child Neurology, 21(4), 358.
15. Durkin, J. P. (2004). Aripiprazole in the treatment of bipolar disorder in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 14(4), 505-506.
16. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S. et al. (2008a). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry, 165(11), 1432-1441.
17. Findling, R. L., Short, E. J., Leskovec, T., Townsend, L. D., Demeter, C. A., McNamara, N. K., et al. (2008b). Aripiprazole in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 18(4), 347-354.
18. Findling, R. L., Kauffman, R. E., Sallee, F. R., Carson, W. H., Nyilas, M., Mallikaarjun, S. et al. (2008c). Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents with Psychiatric Disorders An Open-Label, Dose-Escalation Study. Journal of Clinical Psychopharmacology, 28(4), 441-446.
19. Findling, R. L. (2008d). Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. Journal of Clinical Psychiatry, 69 Suppl 4, 9-14.
20. Findling, R. L., Blumer, J. L., Kauffman, R., Batterson, J. R., Gilbert, D. L., Bramer, S. L. et al. (2004). Pharmacokinetic Effects of Aripiprazole in Children and Adolescents with Conduct Disorder. Poster presented at the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress, Paris, France.
21. Fountoulakis, K. N., Siamouli, M., Kantartzis, S., Panagiotidis, P., Iacovides, A., & Kaprinis, G. S. (2006). Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Annals of Pharmacotherapy, 40(4), 775-777.
22. Gibson, A. P., Crismon, M. L., Mican, L. M., & Fischer, C. (2007). Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. International Clinical Psychopharmacology, 22(2), 101-105.
23. Goodnick, P. J., Jerry, J., & Parra, F. (2002). Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opinion on Pharmacotherapy, 3(5), 479-498.
24. Groff, K., & Coffey, B. J. (2008). Psychosis or atypical neuroleptic malignant syndrome in an adolescent? Journal of Child and Adolescent Psychopharmacology, 18(5), 529-32.
25. Haffejee, S., & Santosh, P. J. (2009). Treatment of alternating hemiplegia of childhood with aripiprazole. Developmental Medicine and Child Neurology, 51(1), 74-77.
26. Hammerman, S., Lam, C., & Caroff, S. N. (2006). Neuroleptic malignant syndrome and aripiprazole. Journal of the American Academy of Child and Adolescent Psychiatry, 45(6), 639-641.
27. Kafantaris, V., Hirsch, J., Saito, E., & Bennett, N. (2005). Treatment of withdrawal dyskinesia. Journal of the American Academy of Child and Adolescent Psychiatry, 44(11), 1102-1103.
28. Kamen, L., Owen, R., Kim, J., Manos, G., Carson, W. H., McQuade, R. D., et al. (2009). Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder. Poster presented at the 162nd Annual Meeting of the American Psychiatric Association, San Francisco, CA.
29. Logue, D. D., Gonzalez, N., Heligman, S. D., McLaughlin, J. V., & Belcher, H. M. (2007). Hyperglycemia in a 7-year-old child treated with aripiprazole. American Journal of Psychiatry, 164(1), 173.
30. Melhem, S., Katz, K., Jameson, A., Shellenbarger, D., & Akhtar, J. (2009). Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole. Pediatric Emergency Care, 25(2), 105-106.
31. Miranda, C. M., & Castiglioni, T. C. (2007). Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients. Revista Médica de Chile, 135(6), 773-776.
32. Murphy, T. K., Bengtson, M. A., Soto, O., Edge, P. J., Sajid, M. W., Shapira, N., et al. (2005). Case series on the use of aripiprazole for Tourette syndrome. International Journal of Neuropsychopharmacology, 8(3), 489-490.
33. Myers, W. C., & Ruiz, R. (2004). Aripiprazole and psychotherapy for delusional disorder, erotomanic type. Journal of the American Academy of Child and Adolescent Psychiatry, 43(9), 1069-1070.
34. Negin, B., & Murphy, T. K. (2005). Priapism associated with oxcarbazepine, aripiprazole, and lithium. Journal of the American Academy of Child and Adolescent Psychiatry, 44(12), 1223-1224.
35. Ortho-McNeil-Janssen Pharmaceuticals, Inc. (2007). Risperdal® prescribing information. Retrieved July 13, 2009, from http://www.risperdal.com/risperdal/shared/pi/risperdal.pdf.
36. Otsuka Pharmaceutical Co. (2008). Abilify® prescribing information. Retrieved July 7, 2009, from http://www.abilify.com/pdf/ pi.aspx.
37. Owen, R., Findling, R. L., Carlson, G., Nyilas, M., Iwamoto, T., Mankoski, R. et al. (2008a). Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder in Children and Adolescents (6-17 Years Old): Results from a Double-Blind, Randomized, Placebo-Controlled Trial (Study CN138-178). Poster presented at the 55th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Chicago, IL.
38. Owen, R., Marcus, R., Aman, M. G., Manos, G., Mankoski, R., Assuncao-Talbott, S. et al. (2008b). Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder in Children and Adolescents (6-17 years old): Results from a Fixed-Dose, Double-Blind, Randomized, Placebo-Controlled Trial (Study CN138-179). Poster presented at the 55th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Chicago, IL.
39. Palakurthi, H. B., Parvin, M. M., & Kaplan, S. (2007). Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clinical Neuropharmacology, 30(1), 47-51.
40. Rugino, T. A., & Janvier, Y. M. (2005). Aripiprazole in children and adolescents: clinical experience. Journal of Child Neurology, 20(7), 603-610.
41. Seo, W. S., Sung, H. M., Sea, H. S., & Bai, D. S. (2008). Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. Journal of Child and Adolescent Psychopharmacology, 18(2), 197-205.
42. Singh, M. K., Delbello, M. P., & Adler, C. M. (2007). Acute dystonia associated with aripiprazole in a child. Journal of the American Academy of Child and Adolescent Psychiatry, 46(3), 306-307.
43. Stigler, K. A., Diener, J. T., Kohn, A. E., Li, L., Erickson, C. A., Posey, D. J. et al. (2009). Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 19(3), 265-274.
44. Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004). Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 455-463.
45. Storch, E. A., Lehmkuhl, H., Geffken, G. R., Touchton, A., & Murphy, T. K. (2008). Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depression and Anxiety, 25(2), 172-174.
46. Strawn, J. R., & Delgado, S. V. (2007). Successful treatment of catatonia with aripiprazole in an adolescent with psychosis. Journal of Child and Adolescent Psychopharmacology, 17(5), 733-735.
47. Tramontina, S., Zeni, C. P., Pheula, G. F., de Souza, C. K., & Rohde, L. A. (2007). Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectrum, 12(10), 758-762.
48. Valicenti-McDermott, M. R., & Demb, H. (2006). Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. Journal of Child and Adolescent Psychopharmacology, 16(5), 549-560.
49. Wahl, R., & Ostroff, R. (2005). Reversal of symptomatic hyperprolactinemia by aripiprazole. American Journal of Psychiatry, 162(8), 1542-1543.
50. Werner, C., Nyilas, M., Forbes, R. A., Jin, N., Johnson, B., Owen, R., et al. (2008). Long-Term Efficacy and Safety of Aripiprazole in Pediatric Patients with Bipolar I Disorder. Poster presented at the XXVIth Congress Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany.
51. Woods, S. W., Tully, E. M., Walsh, B. C., Hawkins, K. A., Callahan, J. L., Cohen, S. J., et al. (2007). Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. British Journal of Psychiatry, 51 Suppl, s96-s101.
52. Yoo, H. K., Choi, S. H., Park, S., Wang, H. R., Hong, J. P., & Kim, C. Y. (2007). An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. Journal of Clinical Psychiatry, 68(7), 1088-1093.
53. Yoo, H. K., Kim, J. Y., & Kim, C. Y. (2006). A pilot study of aripiprazole in children and adolescents with Tourette's disorder. Journal of Child and Adolescent Psychopharmacology, 16(4), 505-506.